Confidence in Moderna and Merck & Co.'s novel individualized neoantigen therapy (INT) combination with Keytruda has grown after the companies unveiled new three-year data in melanoma patients.
The candidate mRNA-4157 (V940) is a potential first-in-class INT which is important for Merck as it looks to extend its dominance in cancer immunotherapy and vital for Moderna as it seeks
Key Takeaways
-
Moderna and Merck believe they can be first with a neoantigen-based cancer immunotherapy
-
The updated Phase II results confirm its advantages over Keytruda monotherapy after three years
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?